Global Blood Therapeutics, Inc GBT

ProjectSyndicate Premium

Why get subbed to me on Tradingview? -TOP author on TradingView -2000+ ideas published -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -before/after analysis -24/7 uptime so constant updates 🎁Please hit the like...

MarketMoversReport

GBT, PFE: Global Blood Therapeutics, Inc.; Pfizer, Inc. 2022-08-08 06:45:00 Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

AwesomeAvani

from long-term consolidation Healthcare and Biotechnology sectors have been strong Awesome Oscillator and Relative Volume Indicators validate the breakout. Last two or three candles show a pullback entry point. The $ 55 call option for 9 /16 has decreasing volatility and looks reasonable. NASDAQ:GBT

kovpups Pro

What about $GBT by Technique: - The stock has entered stage 1 (Consolidation in progress) and has found support at $26.1, resistance at $36.5. It has been in this corridor since late June 21. - The stock is now trading above the 30-week EMA, which might give us the first signs of a follow-through after the consolidation stage. The break-up of the 30W occurred in...

iqheaven

NASDAQ:GBT Fall wedge breakout. Resistance above. Down trend. I don't know. Will keep watching.

chrisklement Pro

CPI announcement dates and drop in price Sell at 33 and buy back at 30 in a few days

chrisklement Pro

An undervalued company - should drop to 26 to 30 USd in near term then increase to $40

ZsaszTrades Pro+

No joke....2016 Possible Bullish Bat Good R/R here imo

PennyStock101 Premium

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D....

SpHiinX-BD

BUY

BigOonTheBeach Premium

Volume and Price Action Study NASDAQ:GBT

BigOonTheBeach Premium

Studying Price Action NASDAQ:GBT

RocketTickers

GBT: Global Blood Therapeutics, Inc. 2019-11-25 16:03:11 FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

ChaseWallace Pro

Bearish count just to show that I know it's possible Green boxes for green abc Blue boxes for blue ABC I can update this into less scenarios and clean up the future price targets IF and WHEN wave B finishes. I don't know where that will be but if the price data confirms it, it'll give tagets for C before lift off.

ChaseWallace Pro

A mediocre wave 3, 1:1 ratio of wave 1 - I don't see this scenario playing out but regardless selling at 85-86 to buy back in a big dip would be a good idea

ChaseWallace Pro

1 bullish count, big 3rd wave Way too far in the future to be predicting price action but let's see

PennyStock101 Premium

Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle...

kushrolled100 Pro+

Continuing from previous post... It is safe to assume the area of 49-50 has strong support due to multiple down days bouncing back off those price levels. We finally broke through resistance at 53-54 levels but risk a gap-fill. Any dips below 53 should be momentary and needs to close above to continue upwards. Using fib-extensions from Mar 6 and Mar 28, I've...